Sign in
Taking peoplePhase 2

Tests PTC844 against placebo in adults with active rheumatoid arthritis

Tests PTC844 against a placebo in adults with active rheumatoid arthritis.

Key facts

Who runs it
PTC Therapeutics
Where
Cape Town, Kempton Park, and Somerset West, South AfricaSee the 4 sitesAlso in 3 other countries, 22 sites
Trial code
Registry title
Study of PTC844 in Participants With Active Rheumatoid Arthritis
Status
Recruiting
Phase
Phase 2
People taking part
75 people, planned
Started
24 Sept 2026
Expected to end
29 Oct 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • PTC844
  • Placebo
Record updated
6 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with active rheumatoid arthritis to test the safety and effects of PTC844 compared with placebo.

Age
18 to 70 years
Sex
Men and women can join.
Disease stage
Active rheumatoid arthritis with moderate or higher activity (DAS28-CRP score of ≥3.2) and CRP of ≥5 mg/L at screening.
Earlier treatment
People who have not yet had disease-modifying treatment for RA, or who had an inadequate response or could not tolerate disease-modifying antirheumatic drugs. Current disease-modifying drugs must be stable for 30 days before screening and stay unchanged during the study.
Biomarker or test result
CRP of ≥5 mg/L at screening.

Main reasons for not taking part

  • Class IV rheumatoid arthritis
  • Rheumatoid arthritis that began before age 17
  • Blood or bone marrow disorders, low platelets, or a bleeding disorder in the past
  • Other inflammatory joint disease or fibromyalgia
  • Cancer within 5 years before screening (except some skin cancers removed locally)

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Historical diagnosis of RA as per the American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) diagnostic criteria
  • Active RA disease with a threshold of moderate activity or higher as confirmed via DAS28-CRP (score of ≥3.2) at screening
  • Naïve to disease-modifying treatments for RA or have had an inadequate response to background treatment for RA and/or inability to tolerate disease-modifying antirheumatic drugs, as per investigator's discretion
  • Disease-modifying antirheumatic drugs should be stable and unchanged from 30 days prior to the start of the Screening Period and intend to remain stable and unchanged throughout the course of the study
  • CRP of ≥5 milligrams (mg)/liter (L) at screening

Who cannot take part

  • Presence of any clinically significant abnormality at screening, or prior or ongoing medical condition (for example, concomitant illness, psychiatric condition), surgical procedure, medical history, or physical findings that, in the investigator's opinion, could adversely affect the safety of the participant or could impair the assessment of study results
  • Past medical history of blood dyscrasia, bone marrow abnormality and/or suppression, drug induced thrombocytopenia or idiopathic thrombocytopenia, or bleeding diathesis
  • Past medical history of inflammatory joint disease other than RA or fibromyalgia
  • Past medical history of malignancy within 5 years prior to screening, except for nonmelanoma skin cancers cursed via local resection
  • Participant has a known hypersensitivity to any of the ingredients of PTC844 or to any excipients of the study drug
  • Use or intended use of any prescribed disease-modifying treatments for RA within 30 days or 5 half-lives (whichever is longer) before the Screening Period until completion of the Follow-Up Visit, except for methotrexate, low dose prednisone (<10 mg/day), hydroxychloroquine, or sulfasalazine, which are permitted as established background single-therapy medications
  • Rheumatoid arthritis onset at <17 years of age
  • Participants with Class IV RA
  • Use or intended use of a combination of methotrexate, low dose prednisone (<10 mg/day), hydroxychloroquine, or sulfasalazine within 30 days or 5 half-lives (whichever is longer) before the Screening Period until completion of the Follow-Up Visit; Note: Other protocol-defined inclusion/exclusion criteria may apply

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in South Africa

Also in 3 other countries, 22 sites

  • Arthritis Clinical Research Trials CCCape Town, South AfricaContact: Catherine Spargo (principal investigator)Not yet recruiting
  • Dr IC LouwCape Town, South AfricaContact: CI Louw (principal investigator)Not yet recruiting
  • Clinresco Centres (Pty) LtdKempton Park, South AfricaContact: Jennifer Rosa (principal investigator)Not yet recruiting
  • Clinical Trials Network HelderbergSomerset West, South AfricaContact: Gareth Tarr (principal investigator)Not yet recruiting

About the trial

What the trial wants to find out

This study is designed to assess the safety, pharmacokinetics (PK), and biomarker effects of PTC844 compared to placebo in participants with active rheumatoid arthritis (RA).

The 3 groups in the trial

  • PTC844 Low DoseTreatment being tested

    Participants will receive PTC844 at a low dose once daily (QD) orally for 12 weeks.

    Treatment: PTC844

  • PTC844 High DoseTreatment being tested

    Participants will receive PTC844 at a high dose QD orally for 12 weeks.

    Treatment: PTC844

  • PlaceboPlacebo, for comparison

    Participants will receive placebo matching to PTC844 QD orally for 12 weeks.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2A, Proof-of-Concept, Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PTC844 in Participants With Active Rheumatoid Arthritis
Plain-language title
Tests PTC844 against placebo in adults with active rheumatoid arthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT07779616, who can take part
Record updated
6 November 2026